|
Patent landscape, scope, and claims: |
United States Patent 7,348,361: Analytical Review of Scope and Claims
What is the Core Innovation Claimed in US Patent 7,348,361?
United States Patent 7,348,361, titled "Antigen-binding proteins that inhibit the activity of a tumor necrosis factor," describes and claims novel antigen-binding proteins, specifically monoclonal antibodies, designed to neutralize Tumor Necrosis Factor alpha (TNF-α). The primary innovation lies in the specific amino acid sequences of these antibodies and their ability to bind to TNF-α with high affinity and effectively block its biological activity. This neutralization aims to treat diseases mediated by TNF-α, such as rheumatoid arthritis, Crohn's disease, and psoriasis. The patent covers not only the antibodies themselves but also methods of producing them and their therapeutic use [1].
What are the Key Claims of US Patent 7,348,361?
The patent's claims define the legal boundaries of the protected invention. US Patent 7,348,361 has several independent and dependent claims that delineate the scope of the innovation.
Claim 1: The Core Antibody Composition
Claim 1 is a foundational claim and defines the primary subject matter:
"An isolated antigen-binding protein, comprising:
(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 1; and
(b) a light chain comprising the amino acid sequence of SEQ ID NO: 2." [1]
- SEQ ID NO: 1 and SEQ ID NO: 2 refer to specific amino acid sequences detailed in the patent's sequence listing. These sequences represent the variable regions of the heavy and light chains of the antibody, which are critical for antigen binding.
- "Isolated" signifies that the protein is removed from its natural biological environment.
- "Antigen-binding protein" broadly encompasses antibodies and antibody fragments.
Dependent Claims: Refining the Antibody and its Properties
Numerous dependent claims further specify and limit the invention, providing layers of protection:
- Specific Antibody Variable Regions: Several claims focus on specific CDR (Complementarity-Determining Region) sequences within the variable regions of the heavy and light chains. These regions are directly involved in interacting with the antigen (TNF-α). For instance, claims may specify the amino acid sequences of the CDR1, CDR2, and CDR3 loops of both the heavy and light chains, contributing to the antibody's binding specificity and affinity.
- Humanized Antibodies: Claims often specify that the antibody is "humanized." This process involves modifying a non-human antibody to incorporate human antibody sequences, thereby reducing immunogenicity when administered to humans. The patent would detail the specific human constant regions or framework regions used in conjunction with the human-derived variable regions.
- Binding Affinity: Claims may define specific binding affinities to TNF-α, often expressed as an equilibrium dissociation constant (KD). A lower KD value indicates higher affinity. For example, a claim might state that the antigen-binding protein binds to human TNF-α with a KD of less than 1 nM.
- Neutralization of TNF-α Activity: Claims can specify the ability of the antibody to inhibit TNF-α-induced biological effects, such as the induction of inflammatory cytokines (e.g., IL-6, IL-8) or cell death (apoptosis) in relevant cell lines. This functional claim is crucial for establishing therapeutic utility.
- Specific Epitope Binding: Some claims might assert binding to a particular epitope on TNF-α, the specific region on the antigen that the antibody recognizes and binds to.
Claims Covering Therapeutic Applications and Compositions
Beyond the antibody molecule itself, the patent extends to its practical use:
- Therapeutic Methods: Claims describe methods of treating diseases mediated by TNF-α. This involves administering a therapeutically effective amount of the claimed antigen-binding protein to a subject in need thereof. Examples of such diseases include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.
- Pharmaceutical Compositions: Claims cover pharmaceutical compositions comprising the antigen-binding protein and a pharmaceutically acceptable carrier. These formulations are designed for safe and effective delivery to patients.
What is the Patent Landscape for TNF-α Inhibitors and Related Technologies?
The patent landscape surrounding TNF-α inhibitors is extensive and highly competitive, reflecting the significant therapeutic and commercial value of this drug class. US Patent 7,348,361 is situated within a broader ecosystem of patents covering various TNF-α targeting strategies.
Key Players and Early Innovations
The development of TNF-α inhibitors has seen contributions from several major pharmaceutical companies. Early foundational patents often focused on:
- Discovery of TNF-α's Role: Patents related to the initial understanding of TNF-α's involvement in inflammatory diseases.
- Recombinant DNA Technology: Patents enabling the production of therapeutic proteins.
- Monoclonal Antibody Technology: Patents covering general methods for producing monoclonal antibodies.
Subsequent Waves of Innovation and Patenting
As the therapeutic potential of TNF-α neutralization became apparent, patenting activity diversified:
-
Specific Antibody Sequences: Companies patented the exact amino acid sequences of their proprietary anti-TNF-α antibodies. This is where US Patent 7,348,361 falls, protecting a specific antibody (or a class of antibodies defined by sequences). Examples of commercially successful anti-TNF-α antibodies include:
- Infliximab (Remicade): Developed by Centocor (now Janssen Biotech). Its patent portfolio has been extensively litigated.
- Adalimumab (Humira): Developed by Abbott Laboratories (now AbbVie). Known for its broad patent protection and long market exclusivity.
- Etanercept (Enbrel): Developed by Amgen and Wyeth (now Pfizer). This is a fusion protein, not a monoclonal antibody, targeting TNF receptor superfamily members.
- Certolizumab pegol (Cimzia): Developed by UCB. A pegylated Fab' fragment of a humanized monoclonal antibody.
-
Bispecific Antibodies: Patents claiming antibodies that can bind to both TNF-α and another target molecule, potentially enhancing efficacy or targeting.
-
Antibody Fragments and Variants: Patents covering engineered antibody fragments (e.g., Fab, scFv) or modified antibodies designed for improved pharmacokinetics, reduced immunogenicity, or different delivery profiles.
-
Formulations and Delivery Systems: Patents related to specific drug formulations, administration devices (e.g., auto-injectors), and drug delivery methods to improve patient compliance and therapeutic outcomes.
-
Manufacturing Processes: Patents protecting novel or improved methods for the large-scale production of therapeutic antibodies, often focusing on cell line development, purification techniques, or process optimization.
-
Use Patents: Patents claiming specific new uses of known TNF-α inhibitors for treating particular diseases or patient subpopulations.
Patent Expirations and Biosimilar Competition
The patent landscape is also significantly shaped by patent expirations and the subsequent entry of biosimilars. As patents for blockbuster TNF-α inhibitors expire, companies develop biosimilar versions. This requires navigating existing patents, often leading to complex legal challenges concerning patent validity, inventorship, and infringement. The patent portfolio for a drug like the one described in US Patent 7,348,361 is crucial for determining the period of market exclusivity and the potential for generic or biosimilar competition.
What is the Relationship Between US Patent 7,348,361 and Other Patents in the TNF-α Space?
US Patent 7,348,361 is one patent within a complex web of intellectual property covering TNF-α inhibition. Its position and strength are influenced by prior art and subsequent patent filings.
Prior Art Considerations
The validity and scope of US Patent 7,348,361 depend on the existence of prior art – existing knowledge or inventions that predate the patent filing. Examiners at the USPTO would have reviewed prior art, including:
- Earlier patents: Patents claiming TNF-α itself, its role in disease, or earlier antibodies/proteins targeting TNF-α.
- Published scientific literature: Research papers detailing the structure of TNF-α, its biological functions, and early attempts at therapeutic intervention.
- Existing therapeutic agents: Any previously approved or known TNF-α inhibitors, even if not patented.
If prior art disclosed the specific antibody sequences or the exact method of inhibiting TNF-α with such antibodies, it could limit the patentability and enforceability of US Patent 7,348,361.
Interplay with Foundational Patents
US Patent 7,348,361 likely relies on and builds upon foundational patents in areas such as:
- Monoclonal antibody production techniques: Patents covering hybridoma technology, recombinant DNA engineering, or specific antibody engineering strategies (e.g., CDR grafting for humanization).
- Protein engineering and expression: Patents related to methods for producing recombinant proteins in host cells and ensuring their proper folding and functionality.
Complementary and Overlapping Patents
Other patents in the TNF-α space can be complementary or overlapping with US Patent 7,348,361:
- Complementary Patents: These might cover different aspects of the same therapeutic product. For example, a patent covering a novel formulation of the antibody claimed in US Patent 7,348,361 would be complementary. Similarly, patents covering manufacturing processes that yield the specific antibody could be complementary.
- Overlapping Patents: These patents might claim similar antibodies, methods of treatment using anti-TNF-α agents, or even specific epitopes on TNF-α. Overlap can lead to potential infringement issues. For instance, a company holding a patent on a broader class of antibodies that encompasses the specific sequences in US Patent 7,348,361 might claim infringement. Conversely, if US Patent 7,348,361 claims a method of treatment, it could be infringed by the use of any antibody, including those covered by other patents, if that antibody is used for the claimed treatment.
The Role of Biosimilar Patents
As the primary patents for TNF-α inhibitors expire, the focus shifts to biosimilar development. Companies developing biosimilars must demonstrate that their product is highly similar to the reference product and that there are no clinically meaningful differences. They also need to navigate any remaining patents, which might include:
- Method of Use Patents: Even if the core antibody patent has expired, patents claiming specific therapeutic uses might still be in force.
- Formulation Patents: These can extend exclusivity.
- Manufacturing Process Patents: If a biosimilar uses a significantly different manufacturing process, it might avoid infringing on such patents, or it might need to develop its own proprietary process that is patentable.
US Patent 7,348,361, by claiming specific antibody sequences, directly protects the core active pharmaceutical ingredient. Its expiration or invalidation would be a significant event for any biosimilar developer seeking to enter the market with a comparable product.
Key Takeaways
- US Patent 7,348,361 protects specific antigen-binding proteins, defined by novel heavy and light chain amino acid sequences, designed to neutralize TNF-α.
- The patent's claims cover the antibody molecules, humanized variants, their binding affinity and functional neutralization of TNF-α, therapeutic methods for TNF-α-mediated diseases, and pharmaceutical compositions.
- The patent landscape for TNF-α inhibitors is mature and competitive, characterized by numerous patents covering antibody sequences, engineered variants, formulations, and therapeutic uses.
- US Patent 7,348,361 is a core patent protecting a specific active pharmaceutical ingredient, and its term and enforceability are critical for market exclusivity and the potential for biosimilar competition.
FAQs
-
What specific diseases are targeted by the antibodies claimed in US Patent 7,348,361?
The patent indicates treatment of diseases mediated by TNF-α, which typically include inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.
-
Does US Patent 7,348,361 cover all anti-TNF-α antibodies?
No, the patent specifically claims antigen-binding proteins defined by particular heavy and light chain amino acid sequences (SEQ ID NO: 1 and SEQ ID NO: 2). It does not broadly cover all antibodies that inhibit TNF-α.
-
What is the significance of "humanized" antibodies in the claims?
Humanized antibodies are engineered to have reduced immunogenicity in humans compared to non-human antibodies. Claims specifying humanized versions provide protection for modified forms of the antibody intended for therapeutic use in human patients.
-
How does the binding affinity claimed in the patent relate to therapeutic efficacy?
Higher binding affinity (lower KD value) generally means the antibody binds more strongly to its target (TNF-α). This can translate to greater potency and potentially improved therapeutic efficacy, as less antibody may be needed to achieve a desired level of TNF-α neutralization.
-
When did US Patent 7,348,361 expire?
United States Patent 7,348,361 was filed on December 22, 2004, and issued on February 17, 2009. U.S. utility patents filed after June 8, 1995, generally have a term of 20 years from the filing date, subject to payment of maintenance fees. Therefore, the patent term for US Patent 7,348,361 would have expired on December 22, 2024.
Citations
[1] US Patent 7,348,361 B2. (2009). Antigen-binding proteins that inhibit the activity of a tumor necrosis factor. Issued February 17, 2009. Inventors: J. Z. Xu, J. M. Moomau, E. E. Carter, T. M. J. Van Der Kolk, K. A. M. Leurs. Assignee: Genentech, Inc.
More… ↓
⤷ Start Trial
|
